These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17092398)

  • 21. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; A'Hern R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1024s-1030s. PubMed ID: 16467120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
    von Minckwitz G; Untch M; Nüesch E; Loibl S; Kaufmann M; Kümmel S; Fasching PA; Eiermann W; Blohmer JU; Costa SD; Mehta K; Hilfrich J; Jackisch C; Gerber B; du Bois A; Huober J; Hanusch C; Konecny G; Fett W; Stickeler E; Harbeck N; Müller V; Jüni P
    Breast Cancer Res Treat; 2011 Jan; 125(1):145-56. PubMed ID: 21042932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy in breast cancer.
    Charfare H; Limongelli S; Purushotham AD
    Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
    Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant endocrine therapy for breast cancer: medical perspectives.
    Ellis MJ
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4388s-4391s; discussion 4411s-4412s. PubMed ID: 11916229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?
    Levasseur N; Clemons M; Hilton J; Addison C; Robertson S; Ibrahim M; Arnaout A
    Minerva Chir; 2015 Jun; 70(3):181-93. PubMed ID: 25737461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.
    Cappelletti V; Celio L; Bajetta E; Allevi A; Longarini R; Miodini P; Villa R; Fabbri A; Mariani L; Giovanazzi R; Galante E; Greco M; Grazia Daidone M
    Endocr Relat Cancer; 2004 Dec; 11(4):761-70. PubMed ID: 15613450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
    Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
    Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.
    Dixon JM; Anderson TJ; Miller WR
    Eur J Cancer; 2002 Nov; 38(17):2214-21. PubMed ID: 12441257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and future roles of neoadjuvant chemotherapy in operable breast cancer.
    Kim R; Osaki A; Toge T
    Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neoadyuvant endocrine therapy in breast cancer].
    Acevedo F; Herrera ME; Madrid J; Sánchez C
    Rev Med Chil; 2013 Mar; 141(3):367-74. PubMed ID: 23900329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
    van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
    Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
    Tao Y; Klause A; Vickers A; Bae K; Ellis M
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):91-5. PubMed ID: 15994076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients.
    Geisler J; Smith I; Miller W
    J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):93-100. PubMed ID: 22207086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Endocrine Therapy: Who Benefits Most?
    Grossman J; Ma C; Aft R
    Surg Oncol Clin N Am; 2018 Jan; 27(1):121-140. PubMed ID: 29132556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.